{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:15:30Z","timestamp":1783782930912,"version":"3.55.0"},"reference-count":39,"publisher":"IMR Press","issue":"8","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Background: This study was carried out to compare the levels of inflammatory markers in the complete blood count before and after they began receiving duloxetine in patients with fibromyalgia syndrome (FMS). Methods: The patient and control groups were composed of 40 patients diagnosed with FMS in accordance with the 2016 American College of Rheumatology (ACR) criteria and 40 healthy volunteers, respectively. The data collection tools comprised the sociodemographic information form, the fibromyalgia impact questionnaire (FIQ), and the sleep hygiene index (SHI), which were used to assess patients\u2019 sociodemographic characteristics, FMS disease activity, and sleep quality, respectively. The inflammatory markers of the patient group were assessed by complete blood count before and after the duloxetine treatment and compared with those of the control group. Results: The white blood cell (WBC), neutrophil, and lymphocyte counts were significantly higher in the patient group than in the control group (p &lt; 0.001, p = 0.036 and p = 0.004, respectively). Moreover, platelet distribution width (PDW) was significantly lower, whereas mean platelet volume (MPV) was significantly higher in the patient group than in the control group (p &lt; 0.001 for both cases). In addition to patients\u2019 platelet-to-lymphocyte ratio (PLR) values, C-reactive protein (CRP) levels, and white blood cell (WBC) counts decreasing but not significantly (p = 0.083, p = 0.068, and p = 0.065, respectively), their neutrophil-to-lymphocyte ratio (NLR), hemoglobin (Hgb), and hematocrit (Hct) values declined substantially after commencing duloxetine treatment (p = 0.001, p = 0.008, and p = 0.001, respectively). Conclusions: The significant reduction in NLR, Hgb, and Hct levels following duloxetine treatment may indicate that these parameters can be utilized as biomarkers in determining the efficacy of treatment and in the follow-up of the treatment in FMS patients.<\/jats:p>","DOI":"10.31083\/j.fbl2808161","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T07:58:11Z","timestamp":1691740691000},"source":"Crossref","is-referenced-by-count":11,"title":["A Comparative Assessment of the Inflammatory Markers in Patients with Fibromyalgia under Duloxetine Treatment"],"prefix":"10.31083","volume":"28","author":[{"given":"Ferhat","family":"Ege","sequence":"first","affiliation":[{"name":"Department of Pain Medicine, Hatay Training and Research Hospital, 31001 Hatay, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridvan","family":"Isik","sequence":"first","affiliation":[{"name":"Division of Pain Medicine, Department of Physical Medicine and Rehabilitation, Sakarya University School of Medicine, 54100 Sakarya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"key":"ref1","unstructured":"Ortega E, Garc\u00eda JJ, Bote ME, Mart\u00edn-Cordero L, Escalante Y, Saavedra JM, et al. Exercise in fibromyalgia and related inflammatory disorders: known effects and unknown chances. Exercise Immunology Review. 2009; 15: 42\u201365."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Lawson VH, Grewal J, Hackshaw KV, Mongiovi PC, Stino AM. Fibromyalgia syndrome and small fiber, early or mild sensory polyneuropathy. Muscle & Nerve. 2018; 58: 625\u2013630.","DOI":"10.1002\/mus.26131"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Littlejohn G, Guymer E. Neurogenic inflammation in fibromyalgia. Seminars in Immunopathology. 2018; 40: 291\u2013300.","DOI":"10.1007\/s00281-018-0672-2"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"\u0130lg\u00fcn E, Aky\u00fcrek \u00d6, kalkan AO, Demir F, Demirayak M, Bilgi M. Neutrophil\/Lymphocyte Ratio and Platelet\/Lymphocyte Ratio in Fibromyalgia. European Journal of General Medicine. 2016; 13: 100\u2013104.","DOI":"10.15197\/ejgm.1525"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Bath P, Algert C, Chapman N, Neal B, PROGRESS Collaborative Group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke. 2004; 35: 622\u2013626.","DOI":"10.1161\/01.STR.0000116105.26237.EC"},{"key":"ref6","unstructured":"G\u00fcr A, Karako\u00e7 M, Nas K, Remzi, Cevik, Denli A, et al. Cytokines and depression in cases with fibromyalgia. The Journal of Rheumatology. 2002; 29: 358\u2013361."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Clauw DJ, Chrousos GP. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation. 1997; 4: 134\u2013153.","DOI":"10.1159\/000097332"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Sargin G, Senturk T, Yavasoglu I, Kose R. Relationship between neutrophil-lymphocyte, platelet-lymphocyte ratio and disease activity in rheumatoid arthritis treated with rituximab. International Journal of Rheumatic Diseases. 2018; 21: 2122\u20132127.","DOI":"10.1111\/1756-185X.13400"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Kozanoglu E, Coskun Benlidayi I, Eker Akilli R, Tasal A. Is there any link between joint hypermobility and mitral valve prolapse in patients with fibromyalgia syndrome? Clinical Rheumatology. 2016; 35: 1041\u20131044.","DOI":"10.1007\/s10067-015-3024-9"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Akt\u00fcrk S, B\u00fcy\u00fckavc\u0131 R. Evaluation of blood neutrophil-lymphocyte ratio and platelet distribution width as inflammatory markers in patients with fibromyalgia. Clinical Rheumatology. 2017; 36: 1885\u20131889.","DOI":"10.1007\/s10067-017-3647-0"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Bote ME, Garc\u00eda JJ, Hinchado MD, Ortega E. Inflammatory\/stress feedback dysregulation in women with fibromyalgia. Neuroimmunomodulation. 2012; 19: 343\u2013351.","DOI":"10.1159\/000341664"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Metyas SK, Solyman JS, Arkfeld DG. Inflammatory Fibromyalgia: Is it Real? Current Rheumatology Reviews. 2015; 11: 15\u201317.","DOI":"10.2174\/1573397111666150522095004"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Xiao Y, Haynes WL, Michalek JE, Russell IJ. Elevated serum high-sensitivity C-reactive protein levels in fibromyalgia syndrome patients correlate with body mass index, interleukin-6, interleukin-8, erythrocyte sedimentation rate. Rheumatology International. 2013; 33: 1259\u20131264.","DOI":"10.1007\/s00296-012-2538-6"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Rodriguez-Pint\u00f3 I, Agmon-Levin N, Howard A, Shoenfeld Y. Fibromyalgia and cytokines. Immunology Letters. 2014; 161: 200\u2013203.","DOI":"10.1016\/j.imlet.2014.01.009"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Russell IJ, Larson AA. Neurophysiopathogenesis of fibromyalgia syndrome: a unified hypothesis. Rheumatic Diseases Clinics of North America. 2009; 35: 421\u2013435.","DOI":"10.1016\/j.rdc.2009.06.005"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. The American Journal of Cardiology. 2008; 102: 653\u2013657.","DOI":"10.1016\/j.amjcard.2008.05.006"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clinical and Applied Thrombosis\/hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis\/Hemostasis. 2003; 9: 177\u2013190.","DOI":"10.1177\/107602960300900301"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Zhou L, Xiao DM, Qin W, Xie BH, Wang TH, Huang H, et al. The clinical value of hematological markers in rheumatoid arthritis patients treated with tocilizumab. Journal of Clinical Laboratory Analysis. 2019; 33: e22862.","DOI":"10.1002\/jcla.22862"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Korniluk A, Koper-Lenkiewicz OM, Kami\u0144ska J, Kemona H, Dymicka-Piekarska V. Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. Mediators of Inflammation. 2019; 2019: 9213074.","DOI":"10.1155\/2019\/9213074"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Geiss A, Rohleder N, Anton F. Evidence for an association between an enhanced reactivity of interleukin-6 levels and reduced glucocorticoid sensitivity in patients with fibromyalgia. Psychoneuroendocrinology. 2012; 37: 671\u2013684.","DOI":"10.1016\/j.psyneuen.2011.07.021"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, et al. Which white blood cell subtypes predict increased cardiovascular risk? Journal of the American College of Cardiology. 2005; 45: 1638\u20131643.","DOI":"10.1016\/j.jacc.2005.02.054"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Al-Nimer MSM, Mohammad TAM. Correlation of hematological indices and ratios derived from them with FIQR scores in fibromyalgia. Pakistan Journal of Medical Sciences. 2018; 34: 1219\u20131224.","DOI":"10.12669\/pjms.345.15169"},{"key":"ref23","unstructured":"Karaba\u015f \u00c7. Fibromyalji Hastalarinda N\u00f6trofil\/Lenfosit Orani, Platelet\/Lenfosit Orani Ve Ortalama Trombosit Hacminin De\u011ferlendirilmesi. Jamer. 2018; 3: 1\u201310."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Bester J, Pretorius E. Effects of IL-1\u03b2, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Scientific Reports. 2016; 6: 32188.","DOI":"10.1038\/srep32188"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Santimone I, Di Castelnuovo A, De Curtis A, Spinelli M, Cugino D, Gianfagna F, et al. White blood cell count, sex and age are major determinants of heterogeneity of platelet indices in an adult general population: results from the MOLI-SANI project. Haematologica. 2011; 96: 1180\u20131188.","DOI":"10.3324\/haematol.2011.043042"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"I\u015f\u0131k M, \u015eahin H, H\u00fcseyin E. New platelet indices as inflammatory parameters for patients with rheumatoid arthritis. European Journal of Rheumatology. 2014; 1: 144\u2013146.","DOI":"10.5152\/eurjrheumatol.2014.140023"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Yazici S, Yazici M, Erer B, Erer B, Calik Y, Ozhan H, et al. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity. Platelets. 2010; 21: 122\u2013125.","DOI":"10.3109\/09537100903474373"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Ablin J, Neumann L, Buskila D. Pathogenesis of fibromyalgia - a review. Joint Bone Spine. 2008; 75: 273\u2013279.","DOI":"10.1016\/j.jbspin.2007.09.010"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Sayilir S. Remarkable Hematological Laboratory Findings in Patients with Fibromyalgia Syndrome. Turkish Journal of Osteoporosis. 2016; 22: 121.","DOI":"10.4274\/tod.16769"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Su CH, Chen JH, Lan JL, Wang YC, Tseng CH, Hsu CY, et al. Increased Risk of Coronary Heart Disease in Patients with Primary Fibromyalgia and Those with Concomitant Comorbidity-A Taiwanese Population-Based Cohort Study. PLoS ONE. 2015; 10: e0137137.","DOI":"10.1371\/journal.pone.0137137"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Halilo\u011flu S, Carlioglu A, Sahiner E, Karaaslan Y, Kosar A. Mean platelet volume in patients with fibromyalgia. Zeitschrift Fur Rheumatologie. 2014; 73: 742\u2013745.","DOI":"10.1007\/s00393-013-1330-7"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"\u00dc\u00e7eyler N, Burgmer M, Friedel E, Greiner W, Petzke F, Sarholz M, et al. Etiology and pathophysiology of fibromyalgia syndrome: Updated guidelines 2017, overview of systematic review articles and overview of studies on small fiber neuropathy in FMS subgroups. Schmerz (Berlin, Germany). 2017; 31: 239\u2013245.","DOI":"10.1007\/s00482-017-0202-5"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Bradley LA. Pathophysiology of fibromyalgia. The American Journal of Medicine. 2009; 122: S22\u2013S30.","DOI":"10.1016\/j.amjmed.2009.09.008"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, H\u00e4user W, Flu\u00df E, et al. EULAR revised recommendations for the management of fibromyalgia. Annals of the Rheumatic Diseases. 2017; 76: 318\u2013328.","DOI":"10.1136\/annrheumdis-2016-209724"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Maes M, Ringel K, Kubera M, Berk M, Rybakowski J. Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. Journal of Affective Disorders. 2012; 136: 386\u2013392.","DOI":"10.1016\/j.jad.2011.11.016"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Natelson BH, Vu D, Mao X, Weiduschat N, Togo F, Lange G, et al. Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial. The Journal of Pain. 2015; 16: 1211\u20131219.","DOI":"10.1016\/j.jpain.2015.08.004"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Clauw DJ. Fibromyalgia: a clinical review. Journal of the American Medical Association. 2014; 311: 1547\u20131555.","DOI":"10.1001\/jama.2014.3266"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Sarzi-Puttini P, Atzeni F, Masala IF, Salaffi F, Chapman J, Choy E. Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria? Autoimmunity Reviews. 2018; 17: 33\u201335.","DOI":"10.1016\/j.autrev.2017.11.007"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Migliorini F, Maffulli N, Eschweiler J, Tingart M, Driessen A, Colarossi G. BMI but not age and sex negatively impact on the outcome of pharmacotherapy in fibromyalgia: a systematic review. Expert Review of Clinical Pharmacology. 2021; 14: 1029\u20131038.","DOI":"10.1080\/17512433.2021.1929923"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/28\/8\/10.31083\/j.fbl2808161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T13:20:37Z","timestamp":1732713637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/28\/8\/10.31083\/j.fbl2808161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"alternative-id":["S2768-6701(23)00960-7"],"URL":"https:\/\/doi.org\/10.31083\/j.fbl2808161","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]},"article-number":"161"}}